Page 2584 - Hematology_ Basic Principles and Practice ( PDFDrive )
P. 2584

2303.e4  Part XIII  Consultative Hematology


            patient  with  human  immunodeficiency  virus  infection.  Mem  Inst   171.  Sundar S, Reed SG, Singh VP, et al: Rapid accurate field diagnosis of
            Oswaldo Cruz 95:733, 2000.                            Indian visceral leishmaniasis. Lancet 351:563, 1998.
        148.  Lindoso JA, Cunha MA, Queiroz IT, et al: Leishmaniasis-HIV coinfec-  172.  Chappuis F, Rijal S, Soto A, et al: A meta-analysis of the diagnostic
            tion: current challenges. HIV AIDS (Auckl) 8:147–156, 2016.  performance  of  the  direct  agglutination  test  and  rK39  dipstick  for
        149.  Alvar J, Aparicio P, Aseffa A, et al: The relationship between leishmani-  visceral leishmaniasis. BMJ 333:723, 2006.
            asis and AIDS: the second 10 years. Clin Microbiol Rev 21:334, 2008.  173.  World Health Organization: Control of the leishmaniases. World Health
        150.  Mary  C,  Lamouroux  D,  Dunan  S,  et al:  Western  blot  analysis  of   Organ Tech Rep Ser 949:1, 2010.
            antibodies  to  Leishmania  infantum  antigens:  potential  of  the  14-kD   174.  Sundar S, Singh A: Recent developments and future prospects in the
            and 16-kD antigens for diagnosis and epidemiologic purposes. Am J   treatment of visceral leishmaniasis. Ther Adv Infect Dis 3:98–109, 2016.
            Trop Med Hyg 47:764, 1992.                        175.  Copeland  NK,  Aronson  NE:  Leishmaniasis:  treatment  updates  and
        151.  Ma DD, Concannon AJ, Hayes J: Fatal leishmaniasis in renal-transport   clinical practice guidelines review. Curr Opin Infect Dis 28:426–437,
            patient. Lancet 2:311, 1979.                          2015.
        152.  Berenguer J, Gomez-Campdera F, Padilla B, et al: Visceral leishmaniasis   176.  Smith SR, Galloway MJ, Reilly JT, et al: Amiloride prevents ampho-
            (kala-azar) in transplant recipients: case report and review. Transplanta-  tericin B related hypokalaemia in neutropenic patients. J Clin Pathol
            tion 65:1401, 1998.                                   41:494, 1988.
        153.  al-Jurayyan NA, al-Nasser MN, al-Fawaz IM, et al: The haematological   177.  Sundar S, Jha TK, Thakur CP, et al: Oral miltefosine for Indian visceral
            manifestations of visceral leishmaniasis in infancy and childhood. J Trop   leishmaniasis. N Engl J Med 347:1739, 2002.
            Pediatr 41:143, 1995.                             178.  Ritmeijer K, Dejenie A, Assefa Y, et al: A comparison of miltefosine
        154.  Wickramasinghe SN, Abdalla SH, Kasili EG: Ultrastructure of bone   and sodium stibogluconate for treatment of visceral leishmaniasis in an
            marrow in patients with visceral leishmaniasis. J Clin Pathol 40:267,   Ethiopian population with high prevalence of HIV infection. Clin Infect
            1987.                                                 Dis 43:357, 2006.
        155.  Pippard  MJ,  Moir  D,  Weatherall  DJ,  et al:  Mechanism  of  anaemia   179.  Sundar  S,  Jha  TK,  Thakur  CP,  et al:  Injectable  paromomycin  for
            in  resistant  visceral  leishmaniasis.  Ann  Trop  Med  Parasitol  80:317,   visceral leishmaniasis in India. N Engl J Med 356:2571, 2007.
            1986.                                             180.  Melaku Y, Collin SM, Keus K, et al: Treatment of kala-azar in southern
        156.  Saeed  AM,  Khalil  EA,  Elhassan  AM,  et al:  Serum  erythropoietin   Sudan  using  a  17-day  regimen  of  sodium  stibogluconate  combined
            concentration  in  anaemia  of  visceral  leishmaniasis  (kala-azar)  before   with  paromomycin:  a  retrospective  comparison  with  30-day  sodium
            and during antimonial therapy. Br J Haematol 100:720, 1998.  stibogluconate monotherapy. Am J Trop Med Hyg 77:89, 2007.
        157.  Sinha AK, Rijal S, Karki P, et al: Incidence of megaloblastic anaemia   181.  Jimenez-Marco  T,  Fisa  R,  Girona-Llobera  E,  et al:  Transfusion-
            and  its  correction  in  leishmaniasis—a  prospective  study  at  BPKIHS   transmitted leishmaniasis: a practical review. Transfusion 56:S45–S51,
            hospital, Nepal. Indian J Pathol Microbiol 49:528, 2006.  2016.
        158.  Vilela RB, Bordin JO, Chiba AK, et al: RBC-associated IgG in patients   182.  Cardo LJ: Leishmania: risk to the blood supply. Transfusion 46:1641,
            with visceral leishmaniasis (kala-azar): a prospective analysis. Transfusion   2006.
            42:1442, 2002.                                    183.  Simarro  PP,  Cecchi  G,  Paone  M,  et al: The  atlas  of  human  African
        159.  Scatena P, Messina F, Gori S, et al: Visceral leishmaniasis in a patient   trypanosomiasis: a contribution to global mapping of neglected tropical
            treated  for  polyarteritis  nodosa.  Clin  Exp  Rheumatol  21(6  Suppl   diseases. Int J Health Geogr 9:57, 2010.
            32):S121, 2003.                                   184.  Brun R, Blum J, Chappuis F, et al: Human African trypanosomiasis.
        160.  Bhatia  P,  Haldar  D,  Varma  N,  et al:  A  case  series  highlighting  the   Lancet 375:148, 2011.
            relative frequencies of the common, uncommon and atypical/unusual   185.  Franco JR, Simarro PP, Diarra A, et al: Epidemiology of human African
            hematological findings on bone marrow examination in cases of visceral   trypanosomiasis. Clin Epidemiol 6:257–275, 2014.
            leishmaniasis. Mediterr J Hematol Infect Dis 3:e2011035, 2011.  186.  Morrison  LJ,  Marcello  L,  McCulloch  R:  Antigenic  variation  in  the
        161.  Boelaert M, Verdonck K, Menten J, et al: Rapid tests for the diagnosis   African trypanosome: molecular mechanisms and phenotypic complex-
            of  visceral  leishmaniasis  in  patients  with  suspected  disease.  Cochrane   ity. Cell Microbiol 11:1724, 2009.
            Database Syst Rev (6):CD009135, 2014.             187.  Smith AB, Esko JD, Hajduk SL: Killing of trypanosomes by the human
        162.  Srividya G, Kulshrestha A, Singh R, et al: Diagnosis of visceral leish-  haptoglobin-related protein. Science 268:284, 1995.
            maniasis:  developments  over  the  last  decade.  Parasitol  Res  110:1065,   188.  Vanhollebeke  B,  De  Muylder  G,  Nielsen  MJ,  et al:  A  haptoglobin-
            2012.                                                 hemoglobin receptor conveys innate immunity to Trypanosoma brucei
        163.  Nicolle C: Isolement et culture des corps de Leishman. Arch Inst Pasteur   in humans. Science 320:677, 2008.
            Tunis 2:55, 1908.                                 189.  Pays  E,  Vanhollebeke  B:  Human  innate  immunity  against  African
        164.  Evans DA: Handbook on isolation, characterization and cryopreservation   trypanosomes. Curr Opin Immunol 21:493, 2009.
            of Leishmania, Geneva, 1989, World Health Organization.  190.  Smith EE, Malik HS: The apolipoprotein L family of programmed cell
        165.  Belli  A,  Rodriguez  B,  Aviles  H,  et al:  Simplified  polymerase  chain   death and immunity genes rapidly evolved in primates at discrete sites
            reaction  detection  of  new  world  Leishmania  in  clinical  specimens  of   of host-pathogen interactions. Genome Res 19:850, 2009.
            cutaneous leishmaniasis. Am J Trop Med Hyg 58:102, 1998.  191.  Genovese G, Friedman DJ, Ross MD, et al: Association of trypanolytic
        166.  Srivastava P, Mehrotra S, Tiwary P, et al: Diagnosis of Indian visceral   ApoL1  variants  with  kidney  disease  in  African  Americans.  Science
            leishmaniasis  by  nucleic  acid  detection  using  PCR.  PLoS  ONE   329:841, 2010.
            6:e19304, 2011.                                   192.  Pepin  J,  Ethier  L,  Kazadi  C,  et al:  The  impact  of  human  immu-
        167.  Antinori S, Calattini S, Longhi E, et al: Clinical use of polymerase chain   nodeficiency  virus  infection  on  the  epidemiology  and  treatment  of
            reaction performed on peripheral blood and bone marrow samples for   Trypanosoma brucei gambiense sleeping sickness in Nioki, Zaire. Am J
            the diagnosis and monitoring of visceral leishmaniasis in HIV-infected   Trop Med Hyg 47:133, 1992.
            and HIV-uninfected patients: a single-center, 8-year experience in Italy   193.  Meda  HA,  Doua  F,  Laveissiere  C,  et al:  Human  immunodeficiency
            and review of the literature. Clin Infect Dis 44:1602, 2007.  virus  infection  and  human  African  trypanosomiasis:  a  case-control
        168.  Mugasa CM, Laurent T, Schoone GJ, et al: Simplified molecular detec-  study in Cote d’Ivoire. Trans R Soc Trop Med Hyg 89:639, 1995.
            tion of Leishmania parasites in various clinical samples from patients   194.  Chisi JE, Misiri H, Zverev Y, et al: Anaemia in human African try-
            with leishmaniasis. Parasit Vectors 3:13, 2010.       panosomiasis caused by Trypanosoma brucei rhodesiense. East Afr Med J
        169.  Meredith SE, Kroon NC, Sondorp E, et al: Leish-KIT, a stable direct   81:505, 2004.
            agglutination  test  based  on  freeze-dried  antigen  for  serodiagnosis  of   195.  Moore AC, Ryan ET, Waldron MA: Case 20-2002—A 37-year-old man
            visceral leishmaniasis. J Clin Microbiol 33:1742, 1995.  with fever, hepatosplenomegaly, and a cutaneous foot lesion after a trip
        170.  Singh S, Gilman-Sachs A, Chang KP, et al: Diagnostic and prognostic   to Africa. N Engl J Med 346:2069, 2002.
            value of K39 recombinant antigen in Indian leishmaniasis. J Parasitol   196.  Woo PT: The haematocrit centrifuge for the detection of trypanosomes
            81:1000, 1995.                                        in blood. Can J Zool 47:921, 1969.
   2579   2580   2581   2582   2583   2584   2585   2586   2587   2588   2589